Last updated on April 2018

PRTX-100-203 Open-Label Dose Escalation Study in Adult Patients With ITP

Brief description of study

Pre-clinical and clinical evaluations show that PRTX- 100 has biological activity that may lead to improved platelet levels where these are decreased due to immunological pathologies and that PRTX-100 has an acceptable safety profile. In vivo treatment with PRTX-100 has been shown to raise platelet counts in a mouse model of immune thrombocytopenia (ITP). The primary objective of the study is to assess the efficacy of PRTX-100 in terms of platelet response in patients with chronic/persistent ITP.

Clinical Study Identifier: NCT02566603

Contact Investigators or Research Sites near you

Start Over

Richard J. Francovitch, PhD

C te de Nacre Hospital
Caen, France
  Connect »